Topoisomerase I inhibitors in the treatment of gastrointestinal cancer: From intravenous to oral administration

Clinical Colorectal Cancer

Volumn 4, Issue 3, 2004, Pages 163-180

  Kuppens, Isa E L M ^a,b   Beijnen, Jos H ^a,b,c   Schellens, Jan H M ^a,c  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Colorectal cancer; Esophageal cancer; Gastric cancer; Pancreatic cancer

Indexed keywords

ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE; ENZYME INHIBITOR;

BIOAVAILABILITY; CLINICAL TRIAL; DRUG ANTAGONISM; GASTROINTESTINAL TUMOR; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; REVIEW; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CLINICAL TRIALS; DNA TOPOISOMERASES, TYPE I; ENZYME INHIBITORS; GASTROINTESTINAL NEOPLASMS; HUMANS; INFUSIONS, INTRAVENOUS; TREATMENT OUTCOME;

EID: 16544370124     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2004.n.017     Document Type: Review

References (213)

1. Borner M, Scheithauer W, Twelves C, et al. Answering patients' needs: oral alternatives to intravenous therapy. Oncologist 2001; 6(suppl 4):12-16.
2. Topham C, Moore J. Patient preferences for chemotherapy schedules used in the treatment of advanced colorectal cancer - a pilot study. Eur J Cancer Care (Engl) 1997; 6:291-294.
3. Hellriegel ET, Bjornsson TD, Hauck WW. Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies. Clin Pharmacol Ther 1996; 60:601-607.
4. Birner A. Safe administration of oral chemotherapy. Clin J Oncol Nurs 2003; 7:158-162.
5. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. J Clin Oncol 1998; 16:301-308.
6. DeMario MD, Ratain MJ. Oral chemotherapy: rationale and future directions. J Clin Oncol 1998; 16:2557-2567.
7. Friedlander ML, Tattersall MH. Counting the costs of cancer therapy. Eur J Cancer Clin Oncol 1982; 18:1237-1241.
8. Liu G, Franssen E, Fitch MI, et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15:110-115.
9. Paine MF, Khalighi M, Fisher JM, et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 1997; 283:1552-1562.
10. Pantazis P, Hinz HR, Mendoza JT, et al. Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins. Cancer Res 1992; 52:3980-3987.
11. Potmesil M, Liebes L, Drygas J, et al. Pharmacodynamics/pharmacokinetics of intragastric camptothecin analogs in a human cancer zenograft model. Proc Am Asso Cancer Res 1995; 36:445 (Abstract #2652).
12. Houghton PJ, Stewart CF, Zamboni WC, et al. Schedule-dependent efficacy of camptothecins in models of human cancer. Ann N Y Acad Sci 1996; 803:188-201.
13. Zamboni WC, Stewart CF, Cheshire PJ, et al. Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models. Clin Cancer Res 1998; 4:743-753.
14. Stevenson JP, Scher RM, Kosierowski R, et al. Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas. Eur J Cancer 1998; 34:1358-1362.
15. Herben VM, Schellens JH, Swart M, et al. Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors. J Clin Oncol 1999; 17:1897-1905.
16. Creemers GJ, Gerrits CJ, Schellens JH, et al. Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer. J Clin Oncol 1996; 14:2540-2545.
17. Hochster H, Liebes L, Speyer J, et al. Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study. Clin Cancer Res 1997; 3:1245-1252.
18. Kuhn J, Rizzo J, Eckardt J, et al. Phase I bioavailability study of oral topotecan. Proc Am Soc Clin Oncol 1995; 14:474 (Abstract #1538).
19. Schellens JH, Creemers GJ, Beijnen JH, et al. Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. Br J Cancer 1996; 73:1268-1271.
20. Zamboni WC, Stewart CF, Thompson J, et al. Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. J Natl Cancer Inst 1998; 90:505-511.
21. Erickson-Miller CL, May RD, Tomaszewski J, et al. Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro. Cancer Chemother Pharmacol 1997; 39:467-472.
22. Hecht J, Parson M, Rosen LS. A phase II trial of irinotecan (CPT-11) in patients with adenocarcinoma of the esophagus and gastric cardia. Proc Am Soc Clin Oncol 1999; 18:287a (Abstract #1100).
23. Lin LS, Hecht J. A phase II trial of irinotecan in patients with advanced adenocarcinoma of the gastroesophageal (GE) junction. Proc Am Soc Clin Oncol 2000; 19:289a (Abstract #1130).
24. Enzinger PC, Kulke MH, Clark JW, et al. Phase II trial of CPT-11 in previously untreated patients with advanced adenocarcinoma of the esophagus and stomach. Proc Am Soc Clin Oncol 2000; 19:315a (Abstract #1243).
25. Henning Kohne C, Thuss-Patience P, Catane R, et al. Final results of a phase II trial of CPT-11 in patients with advanced gastric cancer. Proc Am Soc Clin Oncol 1999; 18:258a (Abstract #993).
26. Kohne CH, Catane R, Klein B, et al. Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial. Br J Cancer 2003; 89:997-1001.
27. Futatsuki K, Wakui A, Nakao I, et al. Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. Jpn J Cancer Chemother 1994; 21:1033-1038.
28. Wagener DJ, Verdonk HE, Dirix LY, et al. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol 1995; 6:129-132.
29. Sakata Y, Shimada Y, Yoshino M, et al. [A late phase II study of CPT-11, irinotecan hydrochloride, in patients with advanced pancreatic cancer. CPT-11 Study Group on Gastrointestinal Cancer]. Gan To Kagaku Ryoho 1994; 21:1039-1046.
30. Govindan R, Read W, Faust J, et al. Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary report. Oncology (Huntingt) 2003; 17:27-31.
31. Tirona MT, Jatoi A, Cha SS, et al. A phase II trial of CPT-11 and docetaxel in patients with metastatic esophageal cancer: Preliminary toxicity data from the North Central Cancer Treatment Group. Proc Am Soc Clin Oncol 2002; 21:152a (Abstract #605).
32. Jatoi A, Tirona MT, Cha SS, et al. A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia. Int J Gastrointest Cancer 2002; 32:115-123.
33. Hecht JR, Blanke CD, Benson AB, 3rd, et al. Irinotecan and paclitaxel in metastatic adenocarcinoma of the esophagus and gastric cardia. Oncology (Huntingt) 2003; 17:13-15.
34. Chan D, George S, Allison MA, et al. A phase II trial of irinotecan (CPT-11) and paclitaxel in metastatic adenocarcinoma of the esophagus and gastric cardia. Proc Am Soc Clin Oncol 2002; 21 (Abstract #2230).
35. Blanke CD, Haller DG, Benson AB, et al. A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma. Ann Oncol 2001; 12:1575-1580.
36. Findlay MPN, Ackland SP, Gebski V, et al. Phase II study of irinotecan, leucovorin and 5-FU (IFL) in advanced gastric cancer. Proc Am Soc Clin Oncol 2001; 20:134a (Abstract #655).
37. Assersohn L, Rigg A, Cunningham D, et al. A phase II trial of irinotecan and 5-fluorouracil (5FU) and folinic acid (FA) in patients with esophago-gastric carcinoma who had progressed or relapsed within 3 months of 5-FU-based chemotherapy. Proc Am Soc Clin Oncol 2002; 21:(Abstract #157).
38. Pozzo C, Bugat R, Peschel C. Irinotecan in combination with CDDP or 5-FU and folinic acid is active in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Final results of a randomised phase II study. Proc Am Soc Clin Oncol 2001; 20:134a (Abstract #531).
39. Baker J, Ajani JA, Ho L, et al. CPT-11 plus cisplatin as second-line therapy of advanced gastric or GE junction adenocarcinoma (AGCAGEJC). Proc Am Soc Clin Oncol 2001; 20:163a (Abstract #647).
40. Ilson DH, Saltz L, Enzinger P, et al. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 1999; 17:3270-3275.
41. Ajani JA, Fairweather J, Pisters PW, et al. Irinotecan and cisplatin in advanced gastric or gastroesophageal junction carcinoma. Oncology (Huntingt) 2000; 14:19-21.
42. Shirao K, Shimada Y, Kondo H, et al. Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol 1997; 15:921-927.
43. Boku N, Ohtsu A, Shimada Y, et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999; 17:319-323.
44. Kurtz JE, Negrier S, Husseini F, et al. A phase II study of docetaxel-irinotecan combination in advanced pancreatic cancer. Hepatogastroenterology 2003; 50:567-570.
45. Stathopoulos GP, Rigatos SK, Dimopoulos MA, et al. Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer. Ann Oncol 2003; 14:388-394.
46. Cantore M, Rabbi C, Cavazzini G, et al. Irinotecan and oxaliplatin combination therapy in patients with advanced pretreated pancreatic cancer. Proc Am Soc Clin Oncol 2002; 21:96b (Abstract #2197).
47. Rocha Lima CS, Savarese D, Bruckner H, et al. Phase II study of irinotecan and gemcitabine (IrinoGem) in patients with previously untreated advanced and metastatic pancreas cancer. Proc Am Soc Clin Oncol 2000; 19:263a (Abstract #1023).
48. Rocha Lima CM, Savarese D, Bruckner H, et al. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 2002; 20:1182-1191.
49. Kozuch P, Grossbard ML, Barzdins A, et al. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer. Oncologist 2001; 6:488-495.
50. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352:1413-1418.
51. Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352:1407-1412.
52. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343:905-914.
53. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:1041-1047.
54. Tournigand C, Louvet C, Quinaux E, et al. FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): Final results of a phase III study. Proc Am Soc Clin Oncol 2001; 20:124a (Abstract #494).
55. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229-237.
56. Bouzid K, Khalfallah S, Tujakowski J, et al. A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer. Ann Oncol 2003; 14:1106-1114.
57. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23-30.
58. Hurwitz H, Fehrenbacher L, Cartwright T, et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc Am Soc Clin Oncol 2003. Late-breaking abstract located at: www.asco.org/hurwitz_no3646. Abstract #3646.
59. Novel Compounds Improve the Impact of Anti-Cancer Therapy [press release]. Washington, D.C.: American Association of Cancer Research, July 14, 2003. Available at www.aacr.org/1132ag.asp. Accessed on May 14, 2004.
60. Future Oncology. Available at: www.newmedinc.com/. Accessed May 15, 2004.
61. Cunningham D, Humblet Y, Siena S, et al. Cetuximab (C225) alone or in combination with irinotecan (CPT-11), infusional 5-fluorouracil (5-FU) and folinica acid (FA) in patients (pts) with metastatic colorectal (CRC) expressing the epidermal growth factor receptor (EGFR). Preliminary safety and efficacy results. Proc Am Soc Clin Oncol 2003; 22:264 (Abstract #1058).
62. Rothenberg ML, Cox JV, DeVore RF, et al. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 1999; 85:786-795.
63. Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997; 15:251-260.
64. Rothenberg ML, Eckardt JR, Kuhn JG, et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996; 14:1128-1135.
65. Conti JA, Kemeny NE, Saltz LB, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996; 14:709-715.
66. Shimada Y, Yoshino M, Wakui A, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 1993; 11:909-913.
67. Fuchs CS, Moore MR, Harker G, et al. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003; 21:807-814.
68. Pitot HC, Wender DB, O'Connell MJ, et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 1997; 15:2910-2919.
69. Weh HJ, Wilke HJ, Dierlamm J, et al. Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. A multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO). Ann Oncol 1994; 5:233-237.
70. de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997; 15:808-815.
71. Buroker TR, O'Connell MJ, Wieand HS, et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994; 12:14-20.
72. Dumez H, Awada A, van Oosterom A, et al. A phase I and pharmacokinetic (PK) trial of oral formulation of irinotecan administered daily for 5 days every 3 weeks in patients (pts) with solid tumors. Proc Am Soc Clin Oncol 2001; 20:103a (Abstract #408).
73. Van Cutsem E, Pozzo C, Starkhammar H, et al. A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer. Ann Oncol 1998; 9:1199-1204.
74. Fuchs CS. Current and ongoing trials with irinotecan in the United States. Semin Oncol 2003; 30:9-17.
75. Hwang JJ, Eisenberg SG, Marshall JL. Improving the toxicity of irinotecan/5-FU/leucovorin: a 21-day schedule. Oncology (Huntingt) 2003; 17:37-43.
76. Aparicio J, Vicent JM, Maestu I, et al. Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer. Ann Oncol 2003; 14:1121-1125.
77. Comella P, Crucitta E, De Vita F, et al. Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology Group. Ann Oncol 2002; 13:866-873.
78. Becouarn Y, Gamelin E, Coudert B, et al. Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients. J Clin Oncol 2001; 19:4195-4201.
79. Yoshimatsu K, Kato H, Ishibashi K, et al. Second-line chemotherapy with low-dose CPT-11 and cisplatin for colorectal cancer resistant to 5-FU-based chemotherapy. Cancer Chemother Pharmacol 2003; 52:465-468.
80. Van Laethem JL, Raoul JL, Brezault C, et al. Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with pediermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorecal cancer (MCRC). Proc Am Soc Clin Oncol 2003; 22:264 (Abstract #1012).
81. Morabito A, Gattuso D, Sarmiento R, et al. Rofecoxib associated with an antiangiogenic schedule of weekly irinotecan and infusional 5-fluorouracil as second line treatment of patients with metastatic colorectal cancer: Results of a dose-finding study. Proc Am Soc Clin Oncol 2003; 22:326 (Abstract #1311).
82. Gill S, Thomas RR, Goldberg RM. New targeted therapies in gastrointestinal cancers. Curr Treat Options Oncol 2003; 4:393-403.
83. Bevacizumab improves survival in metastatic colorectal cancer patients. Oncology (Huntingt) 2003; 17:972.
84. Berlin JD. Targeting vascular endothelial growth factor in colorectal cancer. Oncology (Huntingt) 2002; 16:13-15.
85. Kerr D. Capecitabine/irinotecan in colorectal cancer: European early-phase data and planned trials. Oncology (Huntingt) 2002; 16:12-15.
86. Tewes M, Schleucher N, Achterrath W, et al. Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study dagger. Ann Oncol 2003; 14:1442-1448.
87. Kerr DJ, ten Bokkel Huinink WW, Ferry DR, et al. A phase I/II study of CPT-11 in combination with capecitabine as first line chemotherapy for metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2002; 21:161a (Abstract #643).
88. Jordan K, Grothey A, Kellner O, et al. Randomized phase II trial of capecitabine plus irinotecan vs capecitabine plus oxaliplatin as firstline therapy in advanced colorectal cancer (ACRC). Results of an interim analysis. Proc Am Soc Clin Oncol 2002; 21:(Abstract #2225).
89. Rothenberg ML. Current status of capecitabine in the treatment of colorectal cancer. Oncology (Huntingt) 2002; 16:16-22.
90. Mackay HJ, Hill M, Twelves C, et al. A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer. Ann Oncol 2003; 14:1264-1269.
91. Bugat R, Douillard JY, Perrier H, et al. TEGAFIRI, a new combination of UFT/LV and irinotecan as first line treatment in patients (pts) with nonresectable metastatic colorectal cancer (CRC): Preliminary results of a multicenter phase II trial. Proc Am Soc Clin Oncol 2003; 22:343 (Abstract #1379).
92. United States Food and Drug Administration. FDA approves erbitux for colorectal cancer. Rockville, MD: Department of Health and Human Services.
93. Adding a humanized antibody to vascular endothelial growth factor (Bevacizumab, Avastin) to chemotherapy improves survival in metastatic colorectal cancer. Clin Colorectal Cancer 2003; 3:85-88.
94. Giantonio BJ, Levy D, O'Dwyer PJ, et al. Bevacizumab (anti-VEGF) plus IFL (irinotecan, fluorouracil, leucovorin) as front-line therapy for advanced colorectal cancer (advCRC): results from the Eastern Cooperative Oncology Group (ECOG) study E2200. Proc Am Soc Clin Oncol 2003; 22:255 (Abstract #1024).
95. United States Food and Drug Administration. FDA approves first angiogenesis inhibitor to treat colorectal cancer. Rockville, MD: Department of Health and Human Services.
96. Reynolds NA, Wagstaff AJ. Cetuximab: in the treatment of metastatic colorectal cancer. Drugs 2004; 64:109-118.
97. Saltz LB, Meropol NJ, Loehrer PJ Sr, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22:1201-1208.
98. Enzinger PC, Ilson DH, Kelsen DP. Chemotherapy in esophageal cancer. Semin Oncol 1999; 26:12-20.
99. Enzinger PC, Ilson DH, Saltz LB, et al. Irinotecan and cisplatin in upper gastrointestinal malignancies. Oncology (Huntingt) 1998; 12:110-113.
100. Ajani JA, Baker J, Pisters PW, et al. Irinotecan plus cisplatin in advanced gastric or gastroesophageal junction carcinoma. Oncology (Huntingt) 2001; 15:52-54.
101. Avidan B, Sonnenberg A, Schnell TG, et al. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma. Am J Gastroenterol 2002; 97:1930-1936.
102. Ajani JA, Faust J, Yao J, et al. Irinotecan/cisplatin followed by 5-FU/paclitaxel/radiotherapy and surgery in esophageal cancer. Oncology (Huntingt) 2003; 17:20-22.
103. Ilson DH, Minsky B, Kelsen D. Irinotecan, cisplatin, and radiation in esophageal cancer. Oncology (Huntingt) 2002; 16:11-15.
104. Kroep JR, Pinedo HM, van Groeningen CJ, et al. Experimental drugs and drug combinations in pancreatic cancer. Ann Oncol 1999; 10 Suppl 4:234-238.
105. Radomski KM, Stewart CF, Panetta JC, et al. Phase I and pharmacokinetic study of oral irinotecan in pediatric patients with solid tumors. Proc Am Soc Clin Oncol 2000; 592a (Abstract #2329).
106. Pitot HC, Adjei AA, Reid JM, et al. Phase I and pharmacokinetic study of a powder-filled capsule (PFC) formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2001; 20:102a (Abstract #403).
107. Berlin J, Benson AB, Rubin E, et al. Phase I safety, pharmacokinetic (PK) and bioavailability (F) study of a semi-solid matrix (SSM) formulations of oral irinotecan in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2003; 22:130 (Abstract #521).
108. Schoemaker N, ten Bokkel Huinink WW, et al, Vernillet L, et al. A phase I and pharmacokinetic (PK) trial of oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients (pts) with solid tumors. Proc Am Soc Clin Oncol 2001; 20:75a (Abstract #295).
109. Drengler RL, Kuhn JG, Schaaf LJ, et al. Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors. J Clin Oncol 1999; 17:685-696.
110. Schoemaker NE, ten Bokkel Huinink WW, Lefebvre P, et al. Phase I study of an oral formulation of irinotecan administered daily for fourteen days every three weeks in patients with advanced solid tumours. Utrecht, The Netherlands: Thesis University Utrecht, 2002.
111. Sharma S, Knight RD, Hollywood E, et al. A phase I and pharmacokinetic study of powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 14 days every 3 weeks in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2001; 20:103a (Abstract #407).
112. Gerrits CJ, Burris H, Schellens JH, et al. Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours. Eur J Cancer 1998; 34:1030-1035.
113. Gerrits CJ, Burris H, Schellens JH, et al. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors. Clin Cancer Res 1998; 4:1153-1158.
114. Creemers GJ, Gerrits CJ, Eckardt JR, et al. Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors. J Clin Oncol 1997; 15:1087-1093.
115. Bowman LC, Stewart CF, Zamboni WC, et al. Toxicity and pharmacodynamics of oral topotecan (potopo) in pediatric patients with relapsed solid tumours. Proc Am Soc Clin Oncol 1996; 15:462 (Abstract #1453).
116. de Jonge MJ, Punt CJ, Gelderblom AH, et al. Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors. J Clin Oncol 1999; 17:2219-2226.
117. Xiong HQ, Tran HT, Madden TL, et al. Phase I and pharmacological study of oral 9-aminocamptothecin colloidal dispersion (NSC 603071) in patients with advanced solid tumors. Clin Cancer Res 2003; 9:2066-2071.
118. Verschraegen CF, Natelson EA, Giovanella BC, et al. A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor. Anticancer Drugs 1998; 9:36-44.
119. Natelson EA, Giovanella BC, Verschraegen CF, et al. Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents. Ann N Y Acad Sci 1996; 803:224-230.
120. Zamboni WC, Bowman LC, Tan M, et al. Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors. Cancer Chemother Pharmacol 1999; 43:454-460.
121. Herben VM, Rosing H, ten Bokkel Huinink WW, et al. Oral topotecan: bioavailablity and effect of food co-administration. Br J Cancer 1999; 80:1380-1386.
122. Daw NC, Lacono LC, Santana VM, et al. Phase I and pharmacokinetic study of oral topotecan (TPT) administered once daily on a ten-day schedule to pediatric patients with solid tumors. Proc Am Soc Clin Oncol 2003; 22:810 (Abstract #3254).
123. Sparreboom A, de Jonge MJ, Punt CJ, et al. Pharmacokinetics and bioavailability of oral 9-aminocamptothecin capsules in adult patients with solid tumors. Clin Cancer Res 1998; 4:1915-1919.
124. Gerrits CJ, Schellens JH, Creemers GJ, et al. The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor. Br J Cancer 1997; 76:946-951.
125. Schellens JH, Maliepaard M, Scheper RJ, et al. Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications. Ann N Y Acad Sci 2000; 922:188-194.
126. Chabot GG. Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 1997; 33:245-259.
127. Kuppens IL, Bonneterre ME, Beijnen JH, et al. Dose-finding phase I clinical and pharmacokinetic study of orally administered irinotecan (CPT-11) once daily for 14 days as a single agent or in combination with capecitabine (CAP) twice daily for 14 days every 3 weeks in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2003; 22:158 (Abstract #634).
128. Creemers GJ, Wanders J, Gamucci T, et al. Topotecan in colorectal cancer: a phase II study of the EORTC early clinical trials group. Ann Oncol 1995; 6:844-846.
129. Rowinsky EK, Baker SD, Burks K, et al. High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: a phase II and pharmacodynamic study. Ann Oncol 1998; 9:173-180.
130. Macdonald JS, Benedetti JK, Modiano M, et al. Phase II evaluation of topotecan in patients with advanced colorectal cancer. A Southwest Oncology Group trial (SWOG 9241). Invest New Drugs 1997; 15:357-359.
131. Verweij J, Wanders J, Calbresi F, et al. Phase II study with topotecan in colorectal cancer. Eur J Cancer 1993; 29:S92 (Abstract #490).
132. Hochster H, Ibrahim J, Liebes L, et al. Phase II study of 21-day topotecan continuous infusion for metastatic colorectal cancer. Proc Am Soc Clin Oncol 1997; 16:290a (Abstract #1032).
133. Sugarman SM, Pazdur R, Daugherty K, et al. A phase II trial of topotecan (TPT) for the treatment of unresectable pancreatic cancer (PT). Proc Am Soc Clin Oncol 1994; 13:224 (Abstract #684).
134. Macdonald JS, Jacobson JL, Ketchel SJ, et al. A phase II trial of topotecan in esophageal carcinoma: a Southwest Oncology Group study (SWOG 9339). Invest New Drugs 2000; 18:199-202.
135. Asbury RF, Lipsitz S, Graham D, et al. Treatment of squamous cell esophageal cancer with topotecan: an Eastern Cooperative Oncology Group Study (E2293). Am J Clin Oncol 2000; 23:45-46.
136. Saltz LB, Schwartz GK, Ilson DH, et al. A phase II study of topotecan administered five times daily in patients with advanced gastric cancer. Am J Clin Oncol 1997; 20:621-625.
137. Benedetti JK, Burris HA, 3rd, Balcerzak SP, et al. Phase II trial of topotecan in advanced gastric cancer: a Southwest Oncology Group study. Invest New Drugs 1997; 15:261-264.
138. Pazdur R, Medgyesy DC, Winn RJ, et al. Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hr continuous infusion weekly for three weeks in metastatic colorectal carcinoma. Invest New Drugs 1998; 16:341-346.
139. Pazdur R, Diaz-Canton E, Ballard WP, et al. Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma. J Clin Oncol 1997; 15:2905-2909.
140. Medgyesy D, Pazdur R, Dakhil S, et al. Phase II trial of 5-day continuous infusion of 9-amino camptothecin (9-AC) in advanced colorectal carcinomas (CRCs). Proc Am Soc Clin Oncol 1998; 17:296a (Abstract #1140).
141. Pitot HC, Knost JA, Mahoney MR, et al. A North Central Cancer Treatment Group Phase II trial of 9-aminocamptothecin in previously untreated patients with measurable metastatic colorectal carcinoma. Cancer 2000; 89:1699-1705.
142. Saltz LB, Kemeny NE, Tong W, et al. 9-Aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma. Cancer 1997; 80:1727-1732.
143. D'Adamo D, Hammond L, Donehower R, et al. Final results of a phase II study of DX-8951f (exatecan mesylate.DX) in advanced pancreatic cancer. Proc Am Soc Clin Oncol 2001; 20:134a (Abstract #532).
144. Konstadoulakis MM, Antonakis PT, Tsibloulis BG, et al. A phase II study of 9-nitrocamptothecin in patients with advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol 2001; 48:417-420.
145. Van Cutsem E, Cunningham D, Ten Bokkel Huinink WW, et al. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). Eur J Cancer 1999; 35:54-59.
146. Burris HA III, Hanauske AR, Johnson RK, et al. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colonyforming units in vitro. J Natl Cancer Inst 1992; 84:1816-1820.
147. Houghton PJ, Cheshire PJ, Myers L, et al. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol 1992; 31:229-239.
148. Giovanella BC, Hinz HR, Kozielski AJ, et al. Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin. Cancer Res 1991; 51:3052-3055.
149. Pantazis P, Kozielski A, Rodriguez R, et al. Therapeutic efficacy of camptothecin derivatives against human malignant melanoma xenografts. Melanoma Res 1994; 4:5-10.
150. Philips PC, Janss A, Kaufmann SH, et al. Topoisomerase I inhibitor schedule dependent activity and determinants of cytotoxicity in human brain tumor cell lines. Proc Am Assoc Cancer Res 1994; 35.
151. Gore M, Oza A, Rustin G, et al. A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. Eur J Cancer 2002; 38:57-63.
152. Clarke-Pearson DL, Van Le L, Iveson T, et al. A phase II study of oral topotecan as a single agent, second-line therapy, administered for five days in patients with advanced ovarian cancer. Proc Am Soc Clin Oncol 1999; 18:368 (Abstract #1421).
153. von Pawel J, Gatzemeier U, Pujol JL, et al. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 2001; 19:1743-1749.
154. Gerrits CJ, Schellens JH, Burris H, et al. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin). Clin Cancer Res 1999; 5:69-75.
155. Wall JG, Burris HA, 3rd, Von Hoff DD, et al. A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days. Anticancer Drugs 1992; 3:337-345.
156. van Warmerdam LJ, Verweij J, Schellens JH, et al. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. Cancer Chemother Pharmacol 1995; 35:237-245.
157. Saltz L, Sirott M, Young C, et al. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J Natl Cancer Inst 1993; 85:1499-1507.
158. Haas NB, LaCreta FP, Walczak J, et al. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly. Cancer Res 1994; 54:1220-1226.
159. van Warmerdam LJ, ten Bokkel Huinink WW, Rodenhuis S, et al. Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion. J Clin Oncol 1995; 13:1768-1776.
160. Abbruzzese JL, Madden T, Sugarman SM, et al. Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor. Clin Cancer Res 1996; 2:1489-1497.
161. Mani S, Iyer L, Janisch L, et al. Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071). Cancer Chemother Pharmacol 1998; 42:84-87.
162. Supko JG, Plowman J, Dykes D, et al. Relationship between teh schedule dependence 9-amino-20(S)-camptothecin antitumor activity in mice and its plasma pharmacokinetics. Proc Am Asso Cancer Res 1992; 33:432 (Abstract #2578).
163. Siu LL, Oza AM, Eisenhauer EA, et al. Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion forumation every 5 weeks. J Clin Oncol 1998; 16:1120-1130.
164. Thomas RR, Dahut W, Harold N, et al. A phase I and pharmacologic study of 9-aminocamptothecin administered as a 120-h infusion weekly to adult cancer patients. Cancer Chemother Pharmacol 2001; 48:215-222.
165. Robert F, Irwin D, Dallaire B, et al. A phase I/II trial of 9-aminocamptothecin (9-AC) utilizing a daily schedule: no response was observed despite achieving pharmokinetic targets. Proc Am Soc Clin Oncol 2000; 19:214a (Abstract #834).
166. O'Reilly E, Hammond L, Donehower R. A phase II study of exatecan mesylate (DX-8951f) in advanced pancreatic cancer. Ann Oncol 2000; 11(suppl):S63.
167. O'Reilly EM, Lenzi R, Mani S, et al. Final results of a phase I study of DX-8951f (DX) and gemcitabine (Gem) in advanced solid tumor malignancies. Proc Am Soc Clin Oncol 2002; 21:99a (Abstract #394).
168. Rowinsky EK, Johnson TR, Geyer CE Jr, et al. DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies. J Clin Oncol 2000; 18:3151-3163.
169. Ishii M, Iwahana M, Mitsui I, et al. Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6. Anticancer Drugs 2000; 11:353-362.
170. Pantazis P, Harris N, Mendoza J, et al. The role of pH and serum albumin in the metabolic conversion of 9-nitrocamptothecin to 9-aminocamptothecin by human hematopoietic and other cells. Eur J Haematol 1995; 55:211-213.
171. Schoffski P, Herr A, Vermorken JB, et al. Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer-significant effect of food intake on the bioavailability of the oral camptothecin analogue. Eur J Cancer 2002; 38:807-813.
172. Zamboni WC, Jung LL, Jin R, et al. Phase I & pharmacokinetic (PK) study of intermittently administered 9-nitrocamptothecin (9NC, Rubitecan) in patients with advanced malignancies. Proc Am Assoc Cancer Res 2001; 20:104a (Abstract #411).
173. Rivkin S, Burris H, Gerstein H, et al. A phase II study of Rubitecan (RFS2000, 9NC, 9-Nitro-20(S)-Camptothecin) in patients with refractory pancreatic cancer. Proc Am Soc Clin Oncol 2000; 19:262a (Abstract #1020).
174. Denis LJ, Tolcher A, Rizzo J, et al. Pharmacokinetic (PK) profile of 9-nitrocamptothecin (9-NC, RFS2000) following oral administration daily for 5 consecutive days every week. Proc Am Assoc Cancer Res 2000; 41:538 (Abstract #328).
175. Stehlin JS, Giovanella BC, Natelson EA, et al. Clinical investigations of RFS 2000 (9-nitor-20-9NC) in patients with advanced pancreatic carcinoma. Proc Am Soc Clin Oncol 1998; 17:263a (Abstract #1012).
176. Stehlin JS, Giovanella BC, Natelson EA, et al. A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer. Int J Oncol 1999; 14:821-831.
177. SuperGen reports results of phase III study of Orathecin(TM) in patients with advanced pancreatic cancer [press release] Super-Gen; May 30, 2003.
178. European Agency for Evaluation of Medicinal Products. Committee for Orphan Medicinal Products. Public summary of positive opinion for orphan designation of rubitecan for the treatment of pancreatic cancer. London: Ligue Nationale Contre le Cancer, June 23, 2003.
179. Rubitecan resistant refractory pancreatic cancer. New and Emerging Technology Briefing. Birmingham, AL: University of Birmingham. Located online at: www.publichealth.bham.ac.uk/horizon/2003reports/Rubitecan.pdf.
180. SuperGen reports approval FDA of Orathecin (rubitecan) capsules [press release] SuperGen; March 26, 2004.
181. Gerrits CJ, Creemers GJ, Schellens JH, et al. Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration. Br J Cancer 1996; 73:744-750.
182. Eckhardt SG, Baker SD, Eckardt JR, et al. Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks. Clin Cancer Res 1998; 4:595-604.
183. Paz-Ares L, Kunka R, DeMaria D, et al. A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion. Br J Cancer 1998; 78:1329-1336.
184. Stevenson JP, DeMaria D, Sludden J, et al. Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion. Ann Oncol 1999; 10:339-344.
185. Khater C, Twelves C, Grochow L, et al. Phase I trial of the topoisomerase I inhibitor GG211 as a 21-day continuous infusion. Proc Am Soc Clin Oncol 1996; 15:483 (Abstract #1536).
186. Hamilton M, Wolf J, Demetri GD, et al. Phase I pharmacokinetics of NX211 (liposomal lurototecan) in patients with solid tumors. Proc Am Soc Clin Oncol 2002; 21:90a (Abstract #357).
187. Goetz AD, Hammond LA, Hao D, et al. A phase I and pharmacokinetic (PK) study of NX211 (liposomal lurototecan) in patients with solid tumors. Proc Am Soc Clin Oncol 2002; 22:98a (Abstract #388).
188. Felton SA, Hammond LA, Hao D, et al. A phase I study of NX211 (liposomal lurtotecan) given as an intravenous (IV) infusion on days 1,8,15, and 22 every six weeks in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2001; 20.
189. MacKenzie MJ, Hirte HW, Siu LL, et al. A phase I study of OSI-211 and cisplatin as intravenous infusions given on days 1, 2 and 3 every 3 weeks in patients with solid cancers. Ann Oncol 2004; 15:665-670.
190. Kehrer DF, Bos AM, Verweij J, et al. Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity. J Clin Oncol 2002; 20:1222-1231.
191. Gamucci T, Paridaens R, Heinrich B, et al. Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: an EORTC-ECSG phase II clinical study. Ann Oncol 2000; 11:793-797.
192. Kobayashi K, Jodrell DI, Ratain MJ. Pharmacodynamic-pharmacokinetic relationships and therapeutic drug monitoring. Cancer Surv 1993; 17:51-78.
193. Kehrer DF, Mathijssen RH, Verweij J, et al. Modulation of irinotecan metabolism by ketoconazole. J Clin Oncol 2002; 20:3122-3129.
194. Santos A, Zanetta S, Cresteil T, et al. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res 2000; 6:2012-2020.
195. Kruijtzer CM, Beijnen JH, Rosing H, et al. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol 2002; 20:2943-2950.
196. Maliepaard M, Scheffer GL, Faneyte IF, et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001; 61:3458-3464.
197. Maliepaard M, van Gastelen MA, de Jong LA, et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 1999; 59:4559-4563.
198. Maliepaard M, van Gastelen MA, Tohgo A, et al. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin Cancer Res 2001; 7:935-941.
199. Hendricks CB, Rowinsky EK, Grochow LB, et al. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res 1992; 52:2268-2278.
200. Arimori K, Kuroki N, Hidaka M, et al. Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats. Pharm Res 2003; 20:910-917.
201. Luo FR, Paranjpe PV, Guo A, et al. Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1. Drug Metab Dispos 2002; 30:763-770.
202. Hoki Y, Fujimori A, Pommier Y. Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines. Cancer Chemother Pharmacol 1997; 40:433-438.
203. Jonker JW, Smit JW, Brinkhuis RF, et al. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 2000; 92:1651-1656.
204. Kuppens IELM, Rosing H, Stokvis E, et al. A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) in combination with 2.0 mg oral topotecan in cancer patients [Abstract]. Br J Pharmacol 2003; 141:355.
205. Gelderblom H, Salazar R, Verweij J, et al. Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors. Clin Cancer Res 2003; 9:4101-4107.
206. Perez RP, Hurwitz H, Nahum K, et al. Phase II trials of J-107088, a non-camptothecin topoisomerase I inhibitor, in irinotecan naive/refractory metastatic colorectal cancer. Proc Am Soc Clin Oncol 2002; 21:159 (Abstract #632).
207. Van Hattum AH, Pinedo HM, Schluper HM, et al. New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer. Int J Cancer 2000; 88:260-266.
208. Sessa C, Hess D, Baselga J, et al. Concerted escalation of dose and dosing-duration in a phase I study of the oral camptothecin gimatecan (ST1481). Proc Am Soc Clin Oncol 2002; 21:87a (Abstract #386).
209. Zhu AX, Ready NE, Clark JW, et al. Phase I trial of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2003; 22:139 (Abstract #557).
210. Scott LC, Soepenberg O, Twelves C, et al. A pharmacological comparison of phase I studies of diflomotecan (BN80915) administered orally and intravenously daily for 5 days every 3 weeks in patients with solid tumours. Proc Am Soc Clin Oncol 2003; 22:133 (Abstract #153).
211. Huchet M, Demarquay D, Coulomb H, et al. The dual topoisomerase inhibitor, BN 80927, is highly potent against cell proliferation and tumor growth. Ann N Y Acad Sci 2000; 922:303-305.
212. Barret JM, Kruczynski A, Etievant C, et al. Synergistic effects of F 11782, a novel dual inhibitor of topoisomerases I and II, in combination with other anticancer agents. Cancer Chemother Pharmacol 2002; 49:479-486.
213. Mistry P, Stewart AJ, Dangerfield W, et al. In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II. Anticancer Drugs 2002; 13:15-28.